MTOR and neoplasm: Besides inhibitors targeting either PI3K or mTOR for tumor therapy, a number of dual PI3K/mTOR inhibitors developed to counteract treatment-induced resistance are currently being tested in phase 1 and 2 clinical trials, comprising apitolisib [418], bimiralisib [419], gedatolisib [420], paxalisib [421], and samotolisib [422].